1070790-89-4 (CYC065,Fadraciclib)

(2R,3S)-3-((6-(((4,6-二甲基吡啶-3-基)甲基)氨基)-9-异丙基-9H-嘌呤-2-基)氨基)戊-2-醇;

CYC065;fadraciclib; CYC065;YET2XNU791;(2R,3S)-3-((6-(((4,6-dimethylpyridin-3-yl)methyl)amino)-9-isopropyl-9H-purin-2-yl)amino)pentan-2-ol;CYC065 free base;GTPL10461;BDBM106950;BCP19571;DB15425;SB19802;US8592581, 1;(2R,3S)-3-[[6-[(4,6-dimethylpyridin-3-yl)methylamino]-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol;2-Pentanol, 3-((6-(((4,6-dimethyl-3-pyri;Fadraciclib (CYC065);CYC-065;EX-A2830;(2R,3S)-3-[(6-{[(4,6-dimethylpyridin-3-yl)methyl]amino}-9-(propan-2-yl)-9H-purin-2-yl)amino]pentan-2-ol;MS-26714;NSC-806387;CYC-065 free base;(2R,3s)-3-[[6-[[(4,6-dimethyl-3-pyridinyl)methyl]amino]-9-(1-methylethyl)-9H-purin-2-yl]amino]-2-pentanol;FADRACICLIB [INN];G16404;(2R,3S)-3-((6-((4,6-dimethylpyridin-3-yl)methylamino)-9-propan-2-ylpurin-2-yl)amino)pentan-2-ol;NSC806387;Cyclin Dependent Kinase Inhibitor 2/5/9 CYC065;1070790-89-4;DB-145750;(2R,3S)-3-((6-(((4,6-dimethylpyridin-3-yl)methyl)amino)-9-(propan-2-yl)-9H-purin-2-yl)amino)pentan-2-ol;HY-101212;FADRACICLIB [WHO-DD];CS-7615;AC-31595;2-Pentanol, 3-((6-(((4,6-dimethyl-3-pyridinyl)methyl)amino)-9-(1-methylethyl)-9H-purin-2-yl)amino)-, (2R,3S)-;BC175840;CHEMBL3655762;SCHEMBL13300946;UNII-YET2XNU791;1070790-89-4 (free base);(2R,3S)-3-({6-[(4,6-dimethylpyridin-3-yl)(methyl)amino]-9-(propan-2-yl)-9H-purin-2-yl}amino)pentan-2-ol;

DLPIYBKBHMZCJI-WBVHZDCISA-N

1S/C21H31N7O/c1-7-17(15(6)29)25-21-26-19(18-20(27-21)28(11-24-18)12(2)3)23-10-16-9-22-14(5)8-13(16)4/h8-9,11-12,15,17,29H,7,10H2,1-6H3,(H2,23,25,26,27)/t15-,17+/m1/s1

O[C@H](C)[C@H](CC)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC1C=NC(C)=CC=1C